<unk>  is an extremely rare aggressive disease, and patients are not expected to live normal lifespans. Before the recent introduction of better treatments, such as alemtuzumab, the median survival time was 7.5 months after diagnosis. More recently, some patients have survived five years and more, although the median survival is still low.
T-cell prolymphocytic leukemia
Aggressive NK-cell leukemia
B-cell prolymphocytic leukemia
T-lymphoblastic leukemia/lymphoma
T-cell acute lymphoblastic leukemia
Precursor B-cell lymphoblastic leukemia
Acute myeloblastic leukemia with maturation
Prolymphocytic leukemia